NMS-03305293 for Solid Tumors
This trial is testing a new cancer drug to see if it is safe and works against different types of cancer.
- Advanced/Metastatic Solid Tumors
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How many individuals are partaking in this empirical research?
"Affirmative, according to clinicaltrials.gov this research endeavour is actively searching for subjects. It was first posted on November 25th 2019 and recently amended on March 14th 2022. The study's objective is to include 150 patients from one location into the trial."
Has NMS-03305293 achieved the green light from the FDA?
"Our team at Power assigned a value of 1 to the safety rating for NMS-03305293, as this is an early clinical trial and there is limited data about its efficacy."
Could patients join the experiment at this time?
"Confirmed. According to information published on clinicaltrials.gov, this trial is presently seeking participants who meet eligibility criteria. The trial was initially listed on November 25th 2019 and has been amended as recently as March 14th 2022. This medical study seeks 150 patients from one location for enrolment into the program."